Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > more competition for TLT
View:
Post by riverrrow on May 31, 2021 10:38pm

more competition for TLT

https://au.finance.yahoo.com/news/successful-test-cancer-killing-drug-115734679.html
Comment by DJDawg on May 31, 2021 11:15pm
Interesting article for sure. Usually when they are testing a drug on zebrafish it is fairly early in the IND enabling work. It might be competition but so many more steps to happen over many years.
Comment by gebremeskel on Jun 01, 2021 11:27am
TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models Published online 2020 Mar 4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139549/
Comment by socksnblonds642 on Jun 01, 2021 12:34pm
There was more info on what a Trosian horse is than what their compound is so I think it's safe to say they are a ways off from Theralase IMO. TLD1433 results will drive everything. It doesn't matter if there are 2 or 3 or 6 other competitors. Unfortunately the market is big enough to support all solutions. Hope they all work. So we just become rich instead of stinking rich. 
Comment by gebremeskel on Jun 01, 2021 1:31pm
You want info? Here's their patent. They are still a long way off from human trials. It works a lot like TLD-1433 except that it gains access to cancer cells by binding with metabolites (sugar and amino acids) rather than transferrin (iron) and it is extremely small, so it can cross the blood-brain barrier. https://patents.google.com/patent/WO2020187913A1/en Inventor   Marc ...more  
Comment by Pandora on Jun 01, 2021 1:59pm
"The compound of the invention can be used in photodynamic therapy for ablation of metabolically-active cells. Once the labelled metabolites are uptaken by the target cells, their activation with visible light leads to singlet oxygen generation and concomitant cell death." "The compounds of the invention can also be used to label cancer cells, immune cells as well as stem cells ...more  
Comment by Eoganacht on Jun 01, 2021 2:15pm
More detailed info : Photoactivatable metabolic warheads enable precise and safe ablation of target cells in vivo https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062536/#MOESM8
Comment by BlueFranky on Jun 01, 2021 2:23pm
Eoganacht. Great to see you back!
Comment by Mikee3003 on Jun 01, 2021 5:30pm
Thanks Eogan, always look forward to the informative research you provide to this board. Please keep up the great work. Thanks, Mikee
Comment by gojotv! on Jun 01, 2021 12:09pm
Thanks for the laugh, riverrow. They've got years of testing and research to do. And they'll need to partner up with laser device company before they can even begin trials. And I'm not too hopeful for their chances of success, since they release a toxin in cancer cells to kill them, where TLD-1433 kills cancer cells with oxygen... much safer for the body. Two possibilities: This one ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250